Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. (2019)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(19)32135-x
PubMed Identifier: 31533906
Publication URI: http://europepmc.org/abstract/MED/31533906
Type: Journal Article/Review
Volume: 394
Parent Publication: Lancet (London, England)
Issue: 10208
ISSN: 0140-6736